2 results
Approved WMORecruiting
Objective: To demonstrate the efficacy of a novel matrix therapy based technology that creates improved wound healing in a clinical donor site model.
Approved WMOWill not start
Primary Objective: - To evaluate the efficacy of PF-06651600 and PF-06700841 at Week 8 in subjects with moderate to severe UC. Secondary Objective(s): - To evaluate the safety and tolerability of PF-06651600 and PF-06700841 in subjects with moderate…